The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDPH.L Regulatory News (DPH)

  • There is currently no data for DPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Dechra Pharmaceuticals plc

1 Dec 2023 11:13

RNS Number : 4160V
Barclays PLC
01 December 2023

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR

MORE

Rule 8.3 of the Takeover Code (the "Code")

1.

KEY INFORMATION

(a)

Full name of discloser:

Barclays PLC.

(b)

Owner or controller of interest and short

positions disclosed, if different from 1(a):

(c)

Name of offeror/offeree in relation to whose

DECHRA PHARMACEUTICALS PLC

relevant securities this form relates:

(d)

If an exempt fund manager connected with an

offeror/offeree, state this and specify identity of

offeror/offeree:

(e)

Date position held/dealing undertaken:

30 Nov 2023

(f)

In addition to the company in 1(c) above, is the discloser making

NO

disclosures in respect of any other party to the offer?

2.

POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)

Interests and short positions in the relevant securities of the offeror or offeree

to which the disclosure relates following the dealing(if any)

Class of relevant security:

1p ordinary

Interests

Short Positions

Number

(%)

Number

(%)

(1)

Relevant securities owned

and/or controlled:

7,482,608

6.57%

1,030,793

0.91%

(2)

Cash-settled derivatives:

and/or controlled:

1,027,037

0.90%

7,434,842

6.53%

(3)

Stock-settled derivatives (including options)

and agreements to purchase/sell:

0

0.00%

0

0.00%

TOTAL:

8,509,645

7.47%

8,465,635

7.43%

(b)

Rights to subscribe for new securities (including directors and other executive

options)

Class of relevant security in relation to

which subscription right exists

Details, including nature of the rights

concerned and relevant percentages:

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

Class of relevant

Purchase/sale

Number of

Price per unit

security

securities

1p ordinary

Purchase

60,331

38.2574 GBP

1p ordinary

Purchase

32,195

38.2468 GBP

1p ordinary

Purchase

16,268

38.2400 GBP

1p ordinary

Purchase

9,926

38.2565 GBP

1p ordinary

Purchase

6,716

38.2600 GBP

1p ordinary

Purchase

5,790

38.2380 GBP

1p ordinary

Purchase

4,000

38.2570 GBP

1p ordinary

Purchase

2,271

38.2476 GBP

1p ordinary

Purchase

96

38.2588 GBP

1p ordinary

Sale

57,873

38.2419 GBP

1p ordinary

Sale

55,337

38.2600 GBP

1p ordinary

Sale

31,623

38.2400 GBP

1p ordinary

Sale

5,195

38.2492 GBP

1p ordinary

Sale

3,233

38.2361 GBP

1p ordinary

Sale

2,301

38.2619 GBP

1p ordinary

Sale

1,715

38.2484 GBP

1p ordinary

Sale

457

38.2362 GBP

1p ordinary

Sale

240

38.2511 GBP

1p ordinary

Sale

185

38.2200 GBP

1p ordinary

Sale

112

38.2500 GBP

(b)

Cash-settled derivative transactions

Class of

Product

Nature of dealing

Number of

Price per

relevant

description

reference

unit

security

securities

1p ordinary

SWAP

Long

185

38.2200 GBP

1p ordinary

SWAP

Long

240

38.2511 GBP

1p ordinary

SWAP

Long

1,226

38.2439 GBP

1p ordinary

SWAP

Long

1,499

38.2407 GBP

1p ordinary

SWAP

Long

3,233

38.2361 GBP

1p ordinary

SWAP

Long

13,995

38.2392 GBP

1p ordinary

SWAP

Long

20,159

38.2493 GBP

1p ordinary

SWAP

Long

30,629

38.2400 GBP

1p ordinary

SWAP

Short

2

38.2638 GBP

1p ordinary

SWAP

Short

88

38.2800 GBP

1p ordinary

SWAP

Short

348

38.2600 GBP

1p ordinary

CFD

Short

2,271

38.2476 GBP

1p ordinary

SWAP

Short

9,924

38.2565 GBP

1p ordinary

SWAP

Short

15,128

38.2400 GBP

1p ordinary

SWAP

Short

22,899

38.2539 GBP

(c)

Stock-settled derivative transactions (including options)

(i)

Writing, selling, purchasing or varying

Class

Product

Writing,

Number

Exercise

Type

Expiry

Option

of

description

purchasing,

of

price

date

money

relevant

selling,

securities

per unit

paid/

security

varying etc

to which

received

option

per unit

relates

(ii)

Exercising

Class of relevant

Product description

Exercising/ exercised against

Number of

Exercise price per

security

securities

unit

(d)

Other dealings (including subscribing for new securities)

Class of relevant

Nature of Dealings

Details

Price per unit (if

security

applicable)

4.

OTHER INFORMATION

(a)

Indemnity and other dealings arrangements

Details of any indemnity or option arrangement, or any agreement or understanding,

formal or informal, relating to relevant securities which may be an inducement to deal

or refrain from dealing entered into by the exempt principal trader making the disclosure and any party

to the offer or any person acting in concert with a party to the offer:

NONE

(b)

Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between

the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights of future acquisition or disposal of any relevant securities to which

any derivative is referenced:

NONE

(c)

Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

01 Dec 2023

Contact name:

Large Holdings Regulatory Operations

Telephone number:

020 3134 7213

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RETEAFAFEFEDFFA
Date   Source Headline
16th Jan 20244:54 pmRNSHolding(s) in Company
16th Jan 20243:29 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 20242:43 pmRNSHolding(s) in Company
16th Jan 20241:25 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 20241:15 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 20241:02 pmGNWForm 8.3 - Dechra Pharmaceuticals PLC
16th Jan 202412:50 pmRNSForm 8.5 (EPT/RI)-Replacement of Dechra
16th Jan 202412:44 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 202412:04 pmRNSHolding(s) in Company
16th Jan 202410:15 amRNSScheme of Arrangement becomes Effective
16th Jan 202410:11 amRNSForm 8.5 (EPT/NON-RI) - Dechra Pharmaceuticals PLC
16th Jan 202410:11 amRNSForm 8.5 (EPT/RI)
16th Jan 20249:20 amRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 20249:04 amRNSForm 8.5 (EPT/RI)-Dechra Pharmaceuticals plc
16th Jan 20249:00 amRNSHolding(s) in Company
16th Jan 20248:12 amRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
16th Jan 20247:39 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc
16th Jan 20247:30 amRNSSuspension - Dechra Pharmaceuticals PLC
15th Jan 20244:51 pmRNSDirector/PDMR Shareholding
15th Jan 20243:51 pmRNSHolding(s) in Company
15th Jan 20243:30 pmGNWForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20243:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20243:03 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20241:57 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20241:46 pmEQSForm 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
15th Jan 202412:35 pmGNWForm 8.3 - Dechra Pharmaceuticals PLC
15th Jan 202412:05 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 202411:51 amRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 202411:25 amRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
15th Jan 20249:58 amRNSForm 8.5 (EPT/NON-RI)
15th Jan 20249:58 amRNSForm 8.5 (EPT/RI)
15th Jan 20249:31 amRNSForm 8.5 (EPT/RI)-Dechra Pharmaceuticals plc
15th Jan 20249:13 amRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20247:29 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc
12th Jan 20244:02 pmRNSCourt sanction of Scheme of Arrangement
12th Jan 20243:30 pmGNWForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20243:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20243:07 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20242:42 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20242:30 pmRNSHolding(s) in Company
12th Jan 20241:38 pmEQSForm 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
12th Jan 20241:24 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 202412:03 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 202410:39 amGNWForm 8.3 - Dechra Pharmaceuticals PLC
12th Jan 202410:39 amRNSForm 8.5 (EPT/RI)
12th Jan 202410:36 amRNSForm 8.5 (EPT/NON-RI)
12th Jan 202410:35 amRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20249:34 amRNSHolding(s) in Company
12th Jan 20249:22 amRNSForm 8.5 (EPT/RI)-Dechra Pharmaceuticals plc
12th Jan 20248:09 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.